<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806741</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-300708</org_study_id>
    <nct_id>NCT00806741</nct_id>
  </id_info>
  <brief_title>Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans</brief_title>
  <official_title>Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoregulation is defined as the ability of a vascular bed to adapt its vascular resistance
      to changes in perfusion pressure. In the eye, several studies have reported that retinal
      blood flow is autoregulated over a wide range of ocular perfusion pressures. The
      investigators recently showed that nitric oxide (NO) is a key metabolite in the regulation of
      vascular tone in the eye and plays an important role in the blood flow autoregulation of the
      choroidal circulation. However, no data is yet available for the optic nerve head. Thus, the
      present study is designed to test the hypothesis that NO plays also a role in optic nerve
      head blood flow autoregulation. Therefore, subjects will perform squatting to increase
      systemic perfusion pressure during administration of either a nitric oxide synthase inhibitor
      (L-NMMA), an α-receptor agonist (phenylephrine) or placebo. Optic nerve head blood flow will
      be continuously measured during the procedure to investigate optic nerve head autoregulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic nerve head pressure-flow relationship</measure>
    <time_frame>in total 6x on 3 study days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NG-monomethyl-L-arginine (L-NMMA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine (L-NMMA)</intervention_name>
    <description>bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>1μg/kg/min, infusion period 20 minutes</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological saline solution (as placebo)</intervention_name>
    <description>infusion period 20 minutes</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Doppler Flowmetry</intervention_name>
    <description>blood flow measurements at the temporal neuroretinal rim of the optic nerve head</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann applanation tonometer</intervention_name>
    <description>intraocular pressure measurements</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>squatting</intervention_name>
    <description>Subjects will perform squatting for 6 minutes while blood flow is measured</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 35 years, nonsmokers

          -  Men and women will be included in equal parts

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal findings in the laboratory testings unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Normal ophthalmic findings, ametropia less than 3 diopters

        Exclusion Criteria:

          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical
             trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug (except intake of oral contraceptives)

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with distribution, metabolism or excretion of study drugs

          -  Blood donation during the previous 3 weeks

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Fuchsjaeger-Mayrl, MD, Univ.Doz.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>L-NG-Monomethyl Arginine</keyword>
  <keyword>Optic Nerve Head blood flow</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Regional blood flow</keyword>
  <keyword>Ocular Physiology</keyword>
  <keyword>Optic Disk</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

